[Q2 2025 Financial and Operational Highlights](index=1&type=section&id=Adaptive%20Biotechnologies%20Reports%20Second%20Quarter%202025%20Financial%20Results) [Second Quarter 2025 Financial Performance](index=1&type=section&id=Second%20Quarter%202025%20Financial%20Performance) Adaptive Biotechnologies reported strong Q2 2025 results, with total revenue up 36% to $58.9 million, driven by MRD segment growth and profitability Financial Metric | Financial Metric | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | **Total Revenue** | $58.9 million | $43.2 million | +36% | | **Net Loss** | $25.6 million | $46.2 million | Improved by 45% | | **Adjusted EBITDA (non-GAAP)** | ($7.2 million) | ($21.4 million) | Improved by 66% | Revenue Segment | Revenue Segment | Q2 2025 Revenue | YoY Growth | | :--- | :--- | :--- | | **MRD** | $49.9 million | +42% | | **Immune Medicine** | $8.9 million | +13% | - The Minimal Residual Disease (MRD) business segment achieved profitability in Q2 2025, reporting an **Adjusted EBITDA of $1.9 million**[5](index=5&type=chunk) - Operating expenses decreased by **7% to $83.9 million** in Q2 2025 from $90.5 million in Q2 2024, with only a 1% increase excluding a prior year impairment charge[6](index=6&type=chunk) [Key Operational Achievements](index=1&type=section&id=Key%20Operational%20Achievements) Operational achievements include a 37% increase in clonoSEQ test volume and strategic integration into Flatiron's OncoEMR - clonoSEQ test volume grew **37% to 25,321 tests** delivered compared to Q2 2024[5](index=5&type=chunk) - Strategic partnerships advanced with the launch and integration of clonoSEQ into Flatiron's OncoEMR, a leading electronic medical record platform for community oncology[5](index=5&type=chunk) - The company recognized **$5.5 million** in MRD pharma regulatory milestone revenue during the quarter[5](index=5&type=chunk) [Updated 2025 Financial Guidance](index=2&type=section&id=2025%20Updated%20Financial%20Guidance) Updated 2025 guidance reflects raised MRD revenue expectations and a lowered total company cash burn forecast Guidance Metric | Guidance Metric | Previous 2025 Range | Updated 2025 Range | | :--- | :--- | :--- | | **MRD Business Revenue** | $180M - $190M | $190M - $200M | | **Total Company Cash Burn** | $50M - $60M | $45M - $55M | - Full-year total company operating expenses, including the cost of revenue, are expected to be between **$335 million and $345 million**[9](index=9&type=chunk) - No revenue guidance is provided for the Immune Medicine business[9](index=9&type=chunk) [Financial Statements](index=5&type=section&id=Financial%20Statements) [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q2 2025 statements show increased revenue and reduced operational and net losses, driven by growth and expense control Condensed Consolidated Statements of Operations (in thousands) | (in thousands) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :--- | :--- | :--- | | **Revenue** | $58,879 | $43,190 | | **Total operating expenses** | $83,915 | $90,508 | | **Loss from operations** | ($25,036) | ($47,318) | | **Net loss** | ($25,593) | ($46,248) | | **Net loss per share** | ($0.17) | ($0.31) | [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The June 30, 2025 balance sheet shows $222.0 million in cash and equivalents, with total assets decreasing from operational cash usage Condensed Consolidated Balance Sheets (in thousands) | (in thousands) | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Cash, cash equivalents & marketable securities** | $221,973 | $255,954 | | **Total current assets** | $261,856 | $283,752 | | **Total assets** | $496,637 | $539,376 | | **Total liabilities** | $317,101 | $336,891 | | **Total shareholders' equity** | $179,536 | $202,485 | [Non-GAAP Financial Measures and Segment Information](index=7&type=section&id=Non-GAAP%20Financial%20Measures%20and%20Segment%20Information) [Reconciliation of Net Loss to Adjusted EBITDA](index=7&type=section&id=Reconciliation%20of%20Net%20Loss%20to%20Adjusted%20EBITDA) Q2 2025 Adjusted EBITDA loss improved to $7.2 million, reflecting higher revenue and lower operating expenses post non-cash adjustments Reconciliation of Net Loss to Adjusted EBITDA (in thousands) | Reconciliation (in thousands) | Three Months Ended June 30, 2025 | | :--- | :--- | | **Net loss attributable to Adaptive** | ($25,614) | | Interest and other income, net | ($2,391) | | Interest expense | $2,948 | | Depreciation and amortization expense | $4,502 | | Share-based compensation expense | $13,359 | | **Adjusted EBITDA** | **($7,196)** | [Segment Performance](index=8&type=section&id=Segment%20Performance) Segment data shows robust MRD growth with 42% revenue increase and positive Adjusted EBITDA, while Immune Medicine had modest growth and improved loss Segment Performance (in thousands) | Segment Performance (in thousands) | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | **MRD Revenue** | $49,938 | $35,284 | | **MRD Adjusted EBITDA** | $1,912 | ($11,289) | | **Immune Medicine Revenue** | $8,941 | $7,906 | | **Immune Medicine Adjusted EBITDA** | ($6,069) | ($7,033) | - The MRD segment's Adjusted EBITDA turned positive in Q2 2025, marking a significant milestone towards profitability[25](index=25&type=chunk)

Core Insights - Adaptive Biotechnologies reported strong financial results for Q2 2025, achieving profitability in its Minimal Residual Disease (MRD) business with significant revenue growth [2][4][8] - The company raised its MRD revenue guidance for the full year 2025, reflecting confidence in continued growth [8] Financial Performance - Total revenue for Q2 2025 was $58.9 million, a 36% increase from Q2 2024 [4] - MRD revenue reached $49.9 million, marking a 42% increase year-over-year, while Immune Medicine revenue was $8.9 million, up 13% [4] - Operating expenses decreased to $83.9 million from $90.5 million in the prior year, a 7% reduction [5] - The net loss for Q2 2025 was $25.6 million, significantly improved from a loss of $46.2 million in Q2 2024 [6] Adjusted EBITDA and Cash Position - Adjusted EBITDA for Q2 2025 was a loss of $7.2 million, an improvement from a loss of $21.4 million in the same quarter last year [7][26] - As of June 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $222.0 million [7] Updated Financial Guidance - The company updated its full-year MRD revenue guidance to a range of $190 million to $200 million, up from the previous range of $180 million to $190 million, indicating an expected annual growth of 31% to 37% [8] - Total company operating expenses for the full year are expected to be between $335 million and $345 million, with cash burn guidance reduced to $45 million to $55 million [9]

Core Insights - Adaptive Biotechnologies Corporation will report its financial results for Q2 2025 on August 5, 2025, after market close [1] - A conference call will follow the financial results announcement, starting at 1:30 p.m. Pacific Time [1] Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on utilizing the adaptive immune system for disease diagnosis and treatment [3] - The company aims to decode the adaptive immune system's genetics to enhance medical capabilities in diagnosing and treating diseases [3] - Its proprietary immune medicine platform is designed to provide scalable, precise, and rapid insights into the adaptive immune system [3] - The company operates in two business segments: Minimal Residual Disease (MRD) and Immune Medicine, targeting diseases such as cancer and autoimmune disorders [3] - The goal is to develop and commercialize immune-driven clinical products tailored to individual patients [3]

Company Performance - Adaptive Biotechnologies (ADPT) has gained approximately 96.8% year-to-date, significantly outperforming the average return of -3.1% for Medical companies [4] - The Zacks Consensus Estimate for ADPT's full-year earnings has increased by 5.5% over the past 90 days, indicating improved analyst sentiment and a stronger earnings outlook [4] - Adaptive Biotechnologies holds a Zacks Rank of 2 (Buy), suggesting it has favorable characteristics to outperform the market in the near term [3] Industry Context - Adaptive Biotechnologies is part of the Medical - Biomedical and Genetics industry, which consists of 495 companies and currently ranks 85 in the Zacks Industry Rank [6] - The average performance of the Medical - Biomedical and Genetics industry has seen a loss of 1.1% year-to-date, highlighting ADPT's superior performance within its industry [6] - Another company in the same sector, Anavex Life Sciences (AVXL), has also shown strong performance with a year-to-date increase of 0.5% and a Zacks Rank of 2 (Buy) [5][6]

Core Viewpoint - The integration of Adaptive Biotechnologies' clonoSEQ test for measurable residual disease (MRD) assessment into Flatiron Health's OncoEMR platform enhances access to MRD testing for clinicians, improving treatment decision-making for blood cancer patients [1][2][3][4]. Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment [8][9]. - Flatiron Health is a healthtech company dedicated to advancing point-of-care solutions in oncology, utilizing data to improve cancer care [10]. Product Integration - The clonoSEQ test will be integrated into OncoEMR, allowing over 4,500 clinicians across 1,000 community-based cancer care locations in the U.S. to order and review MRD testing results directly within the EMR [2][4]. - This integration aims to streamline access to MRD data, enabling community clinicians to make more informed treatment decisions for blood cancer patients [3][4]. Clinical Significance - clonoSEQ is the first FDA-cleared in vitro diagnostic test for detecting and tracking MRD in multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, among other lymphoid cancers [5][6]. - The test can detect one cancer cell in one million healthy cells, providing precise monitoring of MRD over time, which is crucial for predicting patient outcomes and informing treatment strategies [6][7]. Market Impact - The integration of clonoSEQ into OncoEMR is expected to enhance the efficiency of testing workflows and provide real-time insights into patients' disease status, ultimately improving patient care in community oncology settings [2][4][11].

Company Overview - Adaptive Biotechnologies (ADPT) shares increased by 12.5% to close at $11.98, with a notable trading volume compared to normal sessions, and a total gain of 16.5% over the past four weeks [1][2] Financial Performance - The company is expected to report a quarterly loss of $0.24 per share, reflecting a year-over-year change of +7.7%, while revenues are projected to be $49.7 million, an increase of 15.1% from the same quarter last year [3] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Adaptive Biotechnologies operates within the Zacks Medical - Biomedical and Genetics industry, where another company, Fortrea Holdings Inc. (FTRE), experienced a 2.4% decline to $5.19, despite a 28% return over the past month [5] - Fortrea Holdings Inc. has a consensus EPS estimate of $0.06 for the upcoming report, representing a significant year-over-year change of +300%, and currently holds a Zacks Rank of 2 (Buy) [6]

Core Viewpoint - Adaptive Biotechnologies (ADPT) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Outlook - The Zacks rating system reflects changes in earnings estimates, which are crucial for predicting near-term stock price movements [2][4]. - The recent upgrade for Adaptive Biotechnologies suggests an improvement in the company's underlying business, likely leading to an increase in stock price [5]. Earnings Estimate Revisions - The Zacks Consensus Estimate for Adaptive Biotechnologies has increased by 5.5% over the past three months, with expected earnings of -$0.87 per share for the fiscal year ending December 2025, showing no year-over-year change [8]. - The correlation between earnings estimate revisions and stock price movements is strong, making it beneficial for investors to track these revisions [6]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - The upgrade to Zacks Rank 2 places Adaptive Biotechnologies in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Summary of Adaptive Biotechnologies (ADPT) FY Conference Call - June 11, 2025 Company Overview - **Company**: Adaptive Biotechnologies (ADPT) - **Industry**: Life Sciences, Diagnostics Key Highlights 1. **Strong Q1 Performance**: The first quarter of 2025 was noted as the best in Adaptive's history, with significant growth in clinical volumes and margin expansion, achieving a volume growth target increase from 25% to 30% [3][4][6] 2. **Average Selling Price (ASP)**: The company is targeting an average selling price of $1,300 for the year, with confidence in achieving this figure based on strong ASP trends [4][30] 3. **EMR Integrations**: Integration of Electronic Medical Records (EMR) is expected to drive significant volume growth, with projections that 50% of order volume will come from EMR integrations by year-end [9][10] 4. **Community Engagement**: 60% of blood cancer patients are treated in community settings, and Adaptive is focusing on expanding its presence in these areas to increase testing frequency [13][14] 5. **New Indications**: The launch of new indications, such as MCL (Mantle Cell Lymphoma) with Medicare coverage, is expected to contribute to growth, with a lifetime value of approximately $15,000 per MCL patient [15][20] 6. **Blood-Based Testing Growth**: Blood-based testing is becoming increasingly important, with a notable increase in testing frequency for ALL (Acute Lymphoblastic Leukemia) from 23% to 37% [25][26] 7. **Payer Contracts**: The company has successfully renegotiated contracts with major payers at or near Medicare rates, ensuring the value of their tests is maintained [27][28] 8. **Partnership with NeoGenomics**: Progress is being made towards a Phase one launch in the second half of the year, with expectations of a 26-27% uplift in volume from this partnership [39][42] 9. **Transition to NovaSeq X**: The transition to NovaSeq X is anticipated to improve margins by 5-8 percentage points within twelve months, with a long-term goal of achieving double-digit margin improvements [58][62] 10. **Research and Development Focus**: The company plans to continue investing in R&D for assay enhancements and blood-based testing, while maintaining a budget of $80-90 million for the entire company [66] Additional Insights - **Market Dynamics**: The company is monitoring the impact of political changes on pharma customers but has not observed any slowdown in trial initiations [38] - **Long-Term Margin Goals**: The company aims for gross margins of over 70% and EBITDA margins exceeding 20% in the MRD segment [70] - **Upcoming Data Readouts**: Significant data readouts are expected at ASH, with studies demonstrating the clinical utility of MRD in guiding therapy decisions [71][73] This summary encapsulates the key points discussed during the conference call, highlighting the company's performance, strategic initiatives, and future outlook in the diagnostics industry.

Core Insights - Adaptive Biotechnologies Corporation announced that its clonoSEQ test for measurable residual disease (MRD) assessment will be featured in 30 presentations at major oncology conferences, including 14 oral presentations [1][2] - The data presented will highlight the clinical actionability of clonoSEQ in multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), showcasing its transformative impact on clinical care and drug development [2][3] Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment [14] - The company aims to leverage its proprietary immune medicine platform to develop clinical diagnostics and therapeutic solutions across various diseases, including cancer and autoimmune disorders [14] Product Information - clonoSEQ is the first FDA-cleared in vitro diagnostic test for detecting and tracking MRD in patients with multiple myeloma and B-cell acute lymphoblastic leukemia, and is also available for chronic lymphocytic leukemia [11][12] - The test can detect one cancer cell in one million healthy cells, providing precise monitoring of MRD over time, which informs treatment decisions and predicts patient outcomes [12] Upcoming Presentations - Key presentations at the ASCO Annual Meeting and EHA Congress will include results from several clinical trials demonstrating the efficacy of MRD-guided therapy in multiple myeloma and CLL [6][8] - Notable studies include the MIDAS trial, which involves 718 transplant-eligible newly diagnosed multiple myeloma patients, and the ADVANCE trial with 306 patients, both focusing on MRD status to guide therapy [6][8]

Company Overview - Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment [3] - The company aims to leverage the adaptive immune system's capabilities, which are considered nature's most finely tuned diagnostic and therapeutic tools for various diseases [3] - Adaptive Biotechnologies operates two business segments: Minimal Residual Disease (MRD) and Immune Medicine, developing products for cancer and autoimmune disorders [3] Upcoming Events - The company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL [1] - Management is scheduled for a fireside chat on June 11 at 5:40 a.m. Pacific Time / 8:40 a.m. Eastern Time, with a live and archived webcast available on the company website [2]